AVRO - AVROバイオ (AVROBIO Inc.)

AVROのニュース

   AVROBIO EPS misses by $0.08  2021/08/05 11:48:56 Seeking Alpha
   Questexs Fierce Life Sciences Clinical Quality Oversight Forum is the First Post-Pandemic In-Person Event for the Clinical Research Community  2021/08/03 17:00:00 Intrado Digital Media
The Annual Gathering features Expert Speakers from Astellas, Merck, Roche/Genentech, Avrobio, Clovis Oncology, Boston Scientific, Bill & Melinda Gates MRI and More The Annual Gathering features Expert Speakers from Astellas, Merck, Roche/Genentech, Avrobio, Clovis Oncology, Boston Scientific, Bill & Melinda Gates MRI and More
   AVROBIO to Present at Two Upcoming Investor Conferences in August  2021/08/02 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences: BTIG Virtual Biotechnology Conference 2021 Date: Monday, Aug. 9, 2021 Time: 3:30 p.m. ET 2021 Wedbush PacGrow Healthcare Virtual Conference Panel: Miss Con-GENE-iality - Updates in Gene Tx Date: W
   AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2021/07/08 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 14,500 shares of the companys common stock to two new employees as inducement awards under the companys 2019 Inducement Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). The sto
   AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2021  2021/06/04 00:00:00 BioSpace
AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted a non-statutory stock option for the purchase of up to an aggregate of 8,250 shares of the companys common stock to one new employee as an inducement award under the companys 2019 Inducement Plan.
   AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2021/07/08 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 14,500 shares of the companys common stock to two new employees as inducement awards under the companys 2019 Inducement Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). The sto
   AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2021  2021/06/04 00:00:00 BioSpace
AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted a non-statutory stock option for the purchase of up to an aggregate of 8,250 shares of the companys common stock to one new employee as an inducement award under the companys 2019 Inducement Plan.
   AVROBIO initiated buy at Needham; estimates more than $2 billion peak sales from pipeline  2021/05/27 18:21:04 Seeking Alpha
   Avrobio (AVRO) Receives a Hold from Leerink Partners  2021/05/18 08:19:26 Smarter Analyst
Leerink Partners analyst Mani Foroohar reiterated a Hold rating on Avrobio (AVRO) on May 13 and set a price target of $10.00. The post Avrobio (AVRO) Receives a Hold from Leerink Partners appeared first on Smarter Analyst .
   Mizuho Securities Thinks Avrobios Stock is Going to Recover  2021/05/14 08:15:57 Smarter Analyst
Mizuho Securities analyst Difei Yang maintained a Buy rating on Avrobio (AVRO) today and set a price target of $28.00. The post Mizuho Securities Thinks Avrobios Stock is Going to Recover appeared first on Smarter Analyst .
   Mid-Afternoon Market Update: Crude Oil Rises 1.5%; AVROBIO Shares Plummet  2021/05/03 14:40:00 Benzinga
Toward the end of trading Monday, the Dow traded up 0.82% to 34,152.49 while the NASDAQ fell 0.36% to 13,912.07. The S&P also rose, gaining 0.41% to …
   Avrobio Plans Registration Trial With Kidney Biopsy Endpoint To Support Potential Full Approval Of Fabry Disease Gene Therapy  2021/05/03 13:42:25 Benzinga
Avrobio Inc (NASDAQ: AVRO ) has provided an update on its regulatory plans for AVR-RD-01, its lentiviral gene therapy for Fabry disease, currently in FAB-GT Phase 2 trial . In March, the FDA granted full approval to Sanofi's SA (NASDAQ: SNY ) Fabrazyme (agalsidase beta) after it received accelerated … Full story available on Benzinga.com
   AVROBIO Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update  2021/03/18 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2020 and provided a business update. “It has been a highly productive period for AVROBIO, with strong new data updates across all our clinical programs, underscoring the transformative potential of our ex vivo lentiviral gene therapies. Most
   AVROBIO Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/03/15 17:51:00 Stock Market Daily
AVROBIO announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑04, an Investigational Gene Therapy for Cystinosis  2021/03/01 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-04, the company’s investigational gene therapy for the treatment of cystinosis. AVR-RD-04 consists of the patient’s own hematopoietic stem cells, genetically modified to express cystinosin, the protein that is deficient in pa

calendar